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Fungal infections have dramatically increased in the last decades in parallel with an
increase of populations with impaired immunity, resulting from medical conditions such
as cancer, transplantation, or other chronic diseases. Such opportunistic infections result
from a complex relationship between fungi and host, and can range from self-limiting to
chronic or life-threatening infections. Modern medicine, characterized by a wide use of
biomedical devices, offers new niches for fungi to colonize and form biofilm communities.
The capability of fungi to form biofilms is well documented and associated with increased
drug tolerance and resistance. In addition, biofilm formation facilitates persistence in
the host promoting a persistent inflammatory condition. With a limited availability of
antifungals within our arsenal, new therapeutic approaches able to address both host and
pathogenic factors that promote fungal disease progression, i.e., chronic inflammation
and biofilm formation, could represent an advantage in the clinical setting. In this paper
we discuss the antifungal properties of myriocin, fulvic acid, and acetylcholine in light of
their already known anti-inflammatory activity and as candidate dual action therapeutics
to treat opportunistic fungal infections.
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Introduction
The population of subjects at risk of developing fungal infections is steadily increasing due to rising
life expectancy and the continuous medical progress in the treatment of serious diseases such as
cancer, transplantation or impairment of immune system (Brown et al., 2012).
Even though advanced medical treatments allow these patients to live longer, the exposure to
surgery and medical devices composed of polymeric materials results in evolved ecological niches
for biofilm-producingmicroorganisms and increases the risk for infectious diseases, including those
caused by opportunistic fungi (Ramage et al., 2006).Candida albicans amongst yeasts andAspergillus
fumigatus amongst molds are still the most common pathogens in the clinical setting (Morace and
Borghi, 2010; Kriengkauykiat et al., 2011; Guinea, 2014), and continue to carry a high mortality
despite the antifungal treatment.
Antifungal resistance is emerging in Candida and Aspergillus species (Arendrup, 2014), and
together with intrinsic or acquired mechanisms, the drug tolerance related to biofilm formation is
emerging as having a crucial role in the failure of treatments (Ramage et al., 2014). Fungal cells within
the biofilms display resistance to azoles and polyenes, at least at therapeutic doses (Taff et al., 2013).
Echinocandins seem to achieve better results against Candida biofilms, but not against A. fumigatus
(Pierce et al., 2013). Thus, the development of new compounds able to overcome the drug-resistance
of biofilms is undoubtedly a current and, even more, a future medical need for the treatment of such
infections.
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Recently, some compounds with known anti-inflammatory
properties have been investigated for their antifungal activity.
This is of particular relevance in the context of fungal infections.
The interplay between fungus and host, i.e., immune system and
inflammatory milieu, is crucial in determining the tolerance or
the disease status (Romani, 2011). Although inflammation is
required to control of fungal infections, its resolution is necessary
to avoid collateral damage to tissues and to restore a homeostatic
environment (Romani, 2011). Drugs displaying dual activity,
antifungal and anti-inflammatory, could thus represent novel
approaches to treat biofilm-related infections. In this work we
discuss the anti-biofilm properties of myriocin, fulvic acid, and
acetylcholine, three compounds recently investigated for their
antifungal activity in the context of fungal biofilms.
Myriocin
Sphingolipids (SPLs) are a class of molecules with structural
and signaling activities conserved from fungi to humans. Many
studies have demonstrated that SPL mediators are involved in
infection-related mechanisms (Mor et al., 2015). Both microbial
and mammalian dysregulation of SPLs play a role in the delicate
relationship between pathogen and host during the infection
process, having an impact on signaling pathways that eventually
lead to commensalism or host damage (Heung et al., 2006).
Fungal SPLs have been implicated in several cellular processes
such as endocytosis, apoptosis, heat stress response, and fungal
pathogenesis (Lattif et al., 2011). In fact, SPLs are part, together
with ergosterol, of plasma membrane domains named lipid rafts
that are crucial for cell signaling and membrane trafficking, and
mediate protein–protein interactions (Farnoud et al., 2015).
Changes in the SPLs content could thus strongly impact the
local membrane structure and alter specific protein localization
such as the GPI-anchored proteins (Singh and Del Poeta, 2011).
These have been extensively studied in C. albicans and are crucial
for adhesion to substrates in the early phases of biofilm formation
(Cabral et al., 2014). Differences in SPLs content have been
observed in planktonic and sessile cells of C. albicans, suggesting
a role for the lipid moiety in biofilm formation and maturation
(Lattif et al., 2011). Lipid rafts have been found to localize
at the hyphal tip, and drugs affecting SPLs biosynthesis, such
as myriocin, lead to defects in hypha formation (Martin and
Konopka, 2004).
Myriocin targets the first step of SPLs de novo biosynthesis,
by inhibiting the enzyme serine palmitoyl transferase (SPT) that
catalyzes the condensation of a fatty acyl CoA with serine, a
common step to both fungal and mammalian SPLs biosynthesis.
Many cell-stress responses cause ceramide, the centralmolecule
of SPL metabolism, to accumulate and trigger the activation of
inflammatory processes (Hannun and Obeid, 2008). High levels
of ceramide are characteristic of several inflammatory diseases.
Animal models showed that myriocin treatment is able to reduce
inflammation by down-regulating ceramide and its related pro-
inflammatory cascade (Jiang et al., 2011; Lee et al., 2012; Caretti
et al., 2014).
Besides this action and similarly to other SPLs metabolism
inhibitors (Groll et al., 1998; Mormeneo et al., 2008), myriocin
has a direct antifungal activity (Martin and Konopka, 2004; Lattif
et al., 2011; de Melo et al., 2013; Sharma et al., 2014). Recently,
Lattif et al. (2011) assessed a potential antibiofilm activity for
the drug. The authors grew C. albicans biofilms in the presence
and absence of various myriocin concentrations and observed a
progressive reduction in biofilm biomass and metabolic activity.
In addition, lipid raft formation was strongly reduced as well as
the C. albicans filamentation (Lattif et al., 2011).
Myriocin has been found to be also active against A. fumigatus
(Cirasola et al., 2014). Administration of myriocin to conidia
resulted in a dose-dependent inhibition of germination, whereas
the treatment of 24 h pre-formed biofilms strongly reduced
the biofilm biomass, as determined by crystal violet assay,
and the metabolic activity. In particular, myriocin led to the
presence of aberrant hyphal structures in A. fumigatus, with
increased branching and reduction in apical hyphal growth.
Hyphal polarization and branching in A. fumigatus, as well as
filamentation in C. albicans, have been shown to be crucial for
virulence and biofilm formation, resulting in more stable biofilms
(Brand, 2012; Riquelme, 2013). The inhibition of SPLmetabolism
disrupts the actin organization at the tip, impacting on normal
hyphal growth and differentiation (Cheng et al., 2001). Moreover,
a deprived quantity of SPLs results in a decrease of SPLs in
lipid rafts with a subsequent reduction of plasma membrane-
anchored proteins that participate in themaintenance of polarized
growth (Momany, 2002). Although the compound is also active
against planktonic fungal cells, all the major SPLs classes seem to
be over-represented in the biofilm-organized cells (Lattif et al.,
2011), suggesting a key role for SPLs in modulating biofilm
formation.
To improve the delivery of myriocin, a highly lipophilic
compound, Strettoi et al. (2010) explored the use of solid
lipid nanocarriers in a mice model of retinitis pigmentosa.
Similarly, other authors observed a decrease in the effective
drug concentration compared with pure compound when using
nanocarrier delivery in a cystic fibrosis mouse model (Caretti
et al., 2014). By treating mice with intratrachea myriocin-loaded
nanocarriers, Caretti et al. (2014) were able to achieve a reduction
of lung infection and inflammation after Pseudomonas aeruginosa
infection.
Due to the poor penetration of biofilm matrix by drugs,
the same nanocarriers were investigated on fungal biofilms.
Nanocarriers improved myriocin delivery into A. fumigatus
biofilms, allowing its distributionwithin few hours even in bottom
layers (Cirasola et al., 2014).
Due to its dual action, anti-inflammatory and antifungal,
myriocin might represent a useful treatment for patients suffering
from chronic diseases that increase the risk of fungal infections.
However, deeper investigations into its administration need to
be performed. Recently de Melo et al. (2013) observed that
prophylaxis treatment with myriocin, in an invertebrate model
of systemic candidiasis, reduces the insect survival (de Melo
et al., 2013). The optimal scenario for the myriocin use could be
late phases of fungal infection as well as pathological situations
characterized by ceramide mediated hyper-inflammation. On the
other hand, the development of myriocin derivatives as well
as other compounds targeting downstream steps in the fungal
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SPL synthesis could increase the specificity of these compounds
against fungal enzymes avoiding host side effects.
Fulvic Acid
Humic substances are commonly found in decaying organic
matter including plants, animal residues, sewage and soil (Snyman
et al., 2002). Although fulvic acids account for 90% of all
humic substances and their biological significance recognized for
many years (van Rensburg et al., 2000), there is still minimal
scientific understanding on which to support the claims of its
biological properties. Oxifulvic acid, a derivate of fulvic acid,
has been shown to elicit antibacterial and antifungal properties
(van Rensburg et al., 2000). However, these formulations contain
numerous toxic elements thatmake their use clinically impossible.
Recently, there has been the development of a pure form of fulvic
acid, carbohydrate derived fulvic acid (CHD-FA), that has been
shown to be safe to use clinically and absent from environmental
contaminants known to be harmful to the host (Gandy et al.,
2011).
An initial randomized double blind controlled trial indicated
that fulvic acid was well-tolerated in patients with eczema,
where side effects were minimal and severity and erythema were
significantly reduced compared with the placebo control (Gandy
et al., 2011). A subsequent phase 1 clinical study carried out to
determine the safety profile of CHD-FA, showed that this agent
was able to elicit anti-inflammatory properties in addition to being
non-toxic when used as an oral formulation (Gandy et al., 2012).
This anti-inflammatory activity was also shown in a rat wound
model, where the use of a topical cream enhanced wound healing
andwas non-toxic during both acute and chronic treatments (Sabi
et al., 2012). However, so far the mechanism by which CHD-FA
elicits the observed immunomodulatory effects is unknown.
Although the anti-inflammatory properties of CHD-FA have
been studied, there are very few reports of the antimicrobial
properties of this agent. Recent studies have shown CHD-FA to be
fungicidal againstC. albicans planktonic and sessile cells at similar
concentrations, indicating good biofilm activity unlike azole
antifungals (Sherry et al., 2012). Time-kill analysis of CHD-FAwas
performed in comparison to the other classes of antifungals, and
whilst caspofungin achieved the greatest kill, CHD-FA elicited its
maximum activity quicker than any of the other agents, which
is of particular benefit in treating systemic infections such as
candidemia, where delayed antifungal therapy coincides with
mortality rates (Morrell et al., 2005). The rapid killing action
was further analyzed by visualizing the uptake of propidium
iodide by the cells, only feasible when the cell membrane has
been compromised. Membrane damage was recorded as early as
10 min following CHD-FA exposure, which also correlates with
the release of intracellular ATP from the cell (Sherry et al., 2012).
To further test the hypothesis of a membrane active compound,
the activity against the C. albicans cell membrane was investigated
using a chitin synthase inhibitor. Chitin is a simple polysaccharide
found in the cell walls of fungi that provides cell structure and
rigidity (Lenardon et al., 2010). It was argued that if the cell
membrane was the target of CHD-FA, then by weakening the cell
by inhibiting its chitin production would increase the exposure
of the cell membrane to the agent and would increase CHD-FA
sensitivity (Sherry et al., 2012). Here it was demonstrated that C.
albicans cells were hyper-susceptible to CHD-FA in the presence
of a chitin synthase inhibitor, a finding that was also observed in
voriconazole treated biofilms (Kaneko et al., 2010). Collectively,
these data suggest that CHD-FA acts through disruption to the
cell membrane. It is therefore feasible to suggest that this agent
may have broad-spectrum antimicrobial activity against a variety
of fungi and bacteria. Indeed, this was the case when CHD-FA
was shown to possess antibacterial activity toward a range of oral
bacterial biofilms, including an in vitro four-species periodontal
biofilm model (Sherry et al., 2013).
Additionally, fulvic acid was shown to be minimally affected
by characterized biofilm resistance mechanisms, including the
extracellular matrix (ECM) and efflux pumps. For example, it
is known that glucans within the cellular matrix hinder the
penetration of azoles through biofilms,with the depletion ofFKS1,
encoding a b-1,3 glucan synthase, increasing the susceptibility
of fluconazole within these communities (Nett et al., 2010a,b).
Overexpression of FKS1, as well as a deletion mutant, was used
to determine the impact of CHD-FA activity. Here it was shown
that this agent’s sensitivity was not compromised by the elevated
expression of FKS1, which is in contrast to azoles, polyenes and
echinocandins, where thematrix sequesters these agents and their
activity is significantly reduced against C. albicans biofilms (Nett
et al., 2010a).
Efflux pumps have been widely shown to play a role in azole
resistance within Candida biofilms, particularly during early
biofilm development both in vitro and in vivo (Ramage et al.,
2002;Mukherjee et al., 2003; Nett et al., 2009). Although CHD-FA
was shown to induce efflux pump activity in C. albicans biofilms,
there was no change in the minimum inhibitory concentration
(MIC) when an efflux pump inhibitor was used, demonstrating
that CHD-FA activity is not compromised by these pumps unlike
other antifungals (Sherry et al., 2012).
Overall, whilst our knowledge base for CHD-FA is relatively
limited, it does appear to have appropriate biological properties
of a broad-spectrum antimicrobial agent and not compromised
by know biofilm resistance mechanisms, which has yet undefined
immunomodulatory capacity. Further in vitro and in vivo studies
are required to determine its safety profile.
Acetylcholine
Bi-directional neurochemical interactions occur between the host
and colonizing microorganisms (Lyte, 2013, 2014a,b; Sandrini
et al., 2015). Many microorganisms share neuro-endocrine
mediator synthesis pathways and recognition receptors with
their human hosts (Lyte, 2013). Therefore, it is hypothesized
that there is constant communication between a vertebrate host
and its microbiota, and a bi-directional influence on behavior
(Freestone, 2013). However, many of the inter-kingdom signaling
molecules and receptors, particularly from the fungal perspective,
remain to be characterized in detail. Furthermore, the biological
consequences of neuro-endocrine signaling in fungi, with respect
to growth and pathogenicity, are only just beginning to be
determined.
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Acetylcholine (ACh) is widely distributed in both prokaryotic
and eukaryotic cells. In mammalian systems, ACh has two
major roles: (1) neuronal ACh acts as a neurotransmitter to
mediate rapid communication between neurons and effector cells
and (2) non-neuronal ACh acts as a local signaling molecule
involved in the regulation of cellular phenotype, modification
of ciliary activity, and modification of cell-cell contact (Wessler
and Kirkpatrick, 2008). In recent years ACh has received
greater attention due to the discovery of the “cholinergic anti-
inflammatory pathway” that has been demonstrated to regulate
immune responses (Borovikova et al., 2000). In this pathway,
ACh released from efferent vagus nerve terminals interacts
with the alpha 7 nicotinic receptor (a7nAChR) on proximal
immune cells resulting in down regulated localized immune
responses. In addition, the efferent vagus nerve interacts with
the splenic nerve to activate a unique ACh-producing memory
phenotype T-cell population, which can propagate ACh mediated
immune-regulation throughout the body (Rosas-Ballina et al.,
2011). Furthermore, as ACh is also produced by cells out
with neural networks, non-neuronal ACh can also play a vital
role in localized immune-regulation through its cytotransmitter
capabilities (de Jonge et al., 2005; Macpherson et al., 2014). In
addition, evidence also suggests that ACh signaling through other
cholinergic receptor subtypes, such as the muscarinic receptors,
can also modulate inflammatory responses in mammalian
systems (Verbout and Jacoby, 2012).
Interestingly, in a recent study, ACh was found to play
multiple roles in the pathogenesis of fungal infections in a
primitive Galleria mellonella infection model. Specifically, ACh
was found to: (i) inhibit C. albicans yeast–to-hyphae transition
and biofilm formation; (ii) promote a rapid and effective cellular
immune response to C. albicans infection; and (iii) regulate
antifungal defenses to limit sepsis induced damage of host tissues
(Rajendran et al., 2015). The fact that ACh can directly act on C.
albicans to inhibit yeast–to-hyphae transition suggests that this
organism possesses a functional ACh receptor. However, the ACh
receptor(s) and the downstream signaling pathway(s) that are
involved in inhibiting C. albicans yeast–to-hyphae transition have
yet to be characterized in detail.
Sequencing of the C. albicans genome has suggested this
organism possesses putative cholinergic receptor genes (Inglis
et al., 2012). Furthermore, pharmacological evidence suggests that
C. albicans may possess a receptor that is homologous to human
muscarinic (M) receptors. Midkiff et al. (2011) demonstrated
that the dopamine receptor antagonist clozapine could inhibit C.
albicans budding-to-hyphal transition by inhibiting a component
of the Efg1 pathway, upstream of the Gpa2 G-alpha subunit,
which the authors hypothesized to be theGpr1G-protein-coupled
receptor (GPCR). However, clozapine has a broad range complex
pharmacological profile. Indeed, it is now known that clozapine
is a weak dopamine D2 receptor inverse agonist/antagonist and
has mixed agonist-antagonist properties on human muscarinic
receptors, with strong evidence that it can act as a potent agonist
of the M1 and M4 receptors in mammalian systems (Zorn et al.,
1994; Olianas et al., 1997, 1999; Miller, 2009; Wiebelhaus et al.,
2012). Therefore, it is interesting to speculate that the observed
effects on C. albicans budded-to-hyphal transition in the study
of Midkiff et al. (2011) may be in fact due to clozapine acting
upon a putative C. albicans cholinergic receptor homologous to
human muscarinic receptors. However, further research aimed
at characterizing the cholinergic receptor mediated signaling
pathways of C. albicans is required to confirm this hypothesis.
There is also substantial evidence to suggest that fungi can
synthesize and release ACh (Horiuchi et al., 2003; Kawashima
and Fujii, 2008). Indeed, sequencing of the C. albicans genome
revealed this organism to possess putative genes for the enzymes
responsible for ACh synthesis; choline acetyltransferase (ChAT)
and carnitine acetyltransferase (CrAT; Inglis et al., 2012).
However, the ACh synthesis machinery of C. albicans remains to
be characterized. Furthermore, the biological functions of fungal
derived ACh remain to be elucidated.
The fact that both C. albicans and its human host both
synthesizeACh andpossess cholinergic receptors lead to speculate
that there is cholinergic mediated bi-directional communication
between the two species in vivo. The role of this cholinergic bi-
directional communication in the maintenance of health and/or
the pathogenesis of C. albicans infections are at present unknown.
The evidence to date suggests the host may utilize ACh to
protect against candidiasis (Rajendran et al., 2015). Although, the
fact that ACh can modulate host immunity (Tracey, 2010) and
also mucosal integrity through the regulation of epithelial cell
phenotype and cell–cell contact (Wessler and Kirkpatrick, 2008),
may also suggest that C. albicans derived ACh may be a potential
virulence factor. Either way, further research into the role of bi-
directional cholinergic signaling mechanisms between C. albicans
and the colonized host is required.
The preliminary data to date imply that cholinergic
mechanisms may be rational novel therapeutic targets to prevent
or treat candidiasis (Rajendran et al., 2015). Indeed, there are
a number of pharmacological agonists and antagonists already
marketed for the treatment of neurodegenerative disorders,
cancers and chronic inflammatory diseases that target cholinergic
receptors (Pohanka, 2012; Zoheir et al., 2012; Sales, 2013; Matera
and Tata, 2014; Russo et al., 2014). Many of these molecules have
already undergone extensive safety and efficacy testing in human
trials. Therefore, one or more of these molecules may be worthy
of investigation for the prevention or treatment of candidiasis
and may offer novel therapeutic approaches beyond conventional
antifungals.
Concluding Remarks
The opportunistic nature of fungal infections highlights the
crucial role of the host immune system in regulating host–fungus
interactions.
Humans suffer from a range of fungal biofilm diseases that
cause high levels of morbidity and mortality. Conventional
antifungal drugs have been demonstrated to ineffective against
fungal biofilms, and alternative strategies are needed to overcome
their intrinsic resistance.
Therefore molecules targeting both fungal biofilm formation
and the host inflammatory response could represent a new
therapeutic approach to treat fungal biofilm-related infections
with broader implications for healthcare applications.
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